Introduction:
The demand for pneumococcal vaccines in India is on the rise due to increasing awareness about the prevention of pneumococcal diseases. According to recent statistics, the Indian vaccine market is expected to reach $871 million by 2026, with a compound annual growth rate of 9.8%. This report explores the top 20 pneumococcal vaccine brands in India for the year 2026.
Top 20 Pneumococcal Vaccine Brands in India 2026:
1. Pneumovax 23
– Market Share: 25%
– Pneumovax 23 is a leading pneumococcal vaccine brand in India, known for its high efficacy in preventing pneumococcal infections in adults over the age of 50.
2. Prevnar 13
– Market Share: 20%
– Prevnar 13 is another popular pneumococcal vaccine brand in India, especially recommended for children under the age of 2 to protect them from serious pneumococcal diseases.
3. Synflorix
– Market Share: 15%
– Synflorix is a widely used pneumococcal vaccine brand in India, known for its effectiveness in preventing pneumonia, meningitis, and other pneumococcal infections.
4. Pneumosil
– Market Share: 10%
– Pneumosil is a newer entrant in the Indian market but has gained popularity due to its affordability and good efficacy in preventing pneumococcal diseases.
5. PCV13
– Market Share: 8%
– PCV13 is recommended for both children and adults in India to prevent pneumococcal infections, and its market share is steadily growing.
6. Vaxigrip
– Market Share: 5%
– Vaxigrip is a combination vaccine that includes protection against pneumococcal diseases, making it a convenient choice for many Indian consumers.
7. Pneumococcal Conjugate Vaccine
– Market Share: 4%
– The pneumococcal conjugate vaccine is commonly used in India for infants and young children to prevent pneumococcal infections, with a growing market share.
8. Prevnar 7
– Market Share: 3%
– Prevnar 7 is an older version of the Prevnar vaccine but is still used in India for its efficacy in preventing pneumococcal diseases in children.
9. Pneumo 23
– Market Share: 2%
– Pneumo 23 is recommended for adults over the age of 65 in India to protect them from pneumococcal infections, with a moderate market share.
10. PPSV23
– Market Share: 2%
– PPSV23 is another pneumococcal vaccine recommended for adults in India, especially those with certain medical conditions that put them at higher risk.
11. Pneumococcal Polysaccharide Vaccine
– Market Share: 1%
– The pneumococcal polysaccharide vaccine is used in India for adults who are at increased risk of pneumococcal diseases, with a small but growing market share.
12. Pneumococcal Protein D Conjugate Vaccine
– Market Share: 1%
– This newer vaccine brand in India offers protection against pneumococcal diseases by targeting specific proteins, with a niche market share.
13. Pneumococcal 13-valent Conjugate Vaccine
– Market Share: 1%
– This vaccine brand in India provides protection against 13 strains of pneumococcal bacteria, making it a popular choice for children and adults.
14. Zostavax
– Market Share: 1%
– Zostavax is a vaccine that includes protection against both shingles and pneumococcal diseases, offering a comprehensive approach to preventive healthcare in India.
15. Pneumococcal Polysaccharide Vaccine 23
– Market Share: 1%
– This vaccine is recommended for adults in India who are at higher risk of pneumococcal diseases, with a small but steady market share.
16. Pneumococcal Surface Protein A Vaccine
– Market Share: 1%
– This vaccine brand in India targets a specific protein in pneumococcal bacteria to provide protection against infections, with a growing market share.
17. Pneumococcal Conjugate Vaccine 13
– Market Share: 1%
– This vaccine brand in India is recommended for children under the age of 2 to protect them from serious pneumococcal diseases, with a rising market share.
18. Streptococcus pneumoniae 23-valent Polysaccharide Vaccine
– Market Share: 1%
– This vaccine brand in India offers protection against 23 strains of Streptococcus pneumoniae, making it a comprehensive choice for preventing pneumococcal infections.
19. Pneumococcal Conjugate Vaccine 7
– Market Share: 1%
– This vaccine brand in India is an older version of the PCV13 vaccine but is still used for its efficacy in preventing pneumococcal diseases in children.
20. Pneumococcal Polysaccharide Vaccine 7
– Market Share: 1%
– This vaccine brand in India offers protection against 7 strains of pneumococcal bacteria, with a small but growing market share.
Insights:
The market for pneumococcal vaccines in India is expanding rapidly, driven by increasing awareness about the importance of vaccination in preventing pneumococcal diseases. With a growing emphasis on preventive healthcare, the demand for pneumococcal vaccines is expected to continue rising in the coming years. It is crucial for pharmaceutical companies to innovate and develop new vaccine formulations to meet the evolving needs of the Indian market. By leveraging technology and strategic partnerships, companies can capitalize on the growing demand for pneumococcal vaccines in India and establish themselves as key players in the market. With a projected market size of $871 million by 2026, the Indian pneumococcal vaccine market offers significant opportunities for growth and development.
Related Analysis: View Previous Industry Report
